Retinopathy of Prematurity - Pipeline Review, H2 2012

Retinopathy of Prematurity – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Retinopathy of Prematurity - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Retinopathy of Prematurity, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Retinopathy of Prematurity. Retinopathy of Prematurity - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Retinopathy of Prematurity.
- A review of the Retinopathy of Prematurity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Retinopathy of Prematurity pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Retinopathy of Prematurity.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Retinopathy of Prematurity pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. SHOW LESS READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Retinopathy Of Prematurity Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Retinopathy Of Prematurity 7
Retinopathy Of Prematurity Therapeutics under Development by Companies 9
Retinopathy Of Prematurity Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Pre-Clinical Stage Products 15
Comparative Analysis 15
Retinopathy Of Prematurity Therapeutics – Products under Development by Companies 16
Retinopathy Of Prematurity Therapeutics – Products under Investigation by Universities/Institutes 17
Companies Involved in Retinopathy Of Prematurity Therapeutics Development 18
Insmed Incorporated 18
Acucela Inc. 19
Gene Signal International SA. 20
EyeGene, Inc. 21
Retinopathy Of Prematurity – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
mecasermin rinfabate - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Drug For Retinopathy Of Prematurity - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
aganirsen - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
propranolol hydrochloride - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
mecasermin - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
inositol niacinate - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
bevacizumab - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
EG-Mirotin - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
betaxolol hydrochloride - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Retinopathy Of Prematurity Therapeutics – Drug Profile Updates 39
Retinopathy Of Prematurity Therapeutics - Dormant Products 40
Retinopathy Of Prematurity – Product Development Milestones 41
Featured News & Press Releases 41
Apr 29, 2008: Acucela Presents Preclinical Data From Retinopathy Study Demonstrating Improvement In Retinal Abnormalities 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 43
Disclaimer 43

List of Tables
Number of Products Under Development for Retinopathy Of Prematurity, H2 2012 7
Products under Development for Retinopathy Of Prematurity – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 17
Insmed Incorporated, H2 2012 18
Acucela Inc., H2 2012 19
Gene Signal International SA., H2 2012 20
EyeGene, Inc., H2 2012 21
Assessment by Monotherapy Products, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 26
Retinopathy Of Prematurity Therapeutics – Drug Profile Updates 39
Retinopathy Of Prematurity Therapeutics – Dormant Products 40

List of Figures
Number of Products under Development for Retinopathy Of Prematurity, H2 2012 7
Products under Development for Retinopathy Of Prematurity – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Pre-Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 22
Assessment by Route of Administration, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Molecule Type, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 26